Terms: = Bone cancer AND FOXO1, Q12778, FOXO1A, 2308, ENSG00000150907, FKH1, FKHR AND Clinical Outcome
4 results:
1. Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease.
Lak NSM; Voormanns TL; Zappeij-Kannegieter L; van Zogchel LMJ; Fiocco M; van Noesel MM; Merks JHM; van der Schoot CE; Tytgat GAM; Stutterheim J
Clin Cancer Res; 2021 Oct; 27(20):5576-5585. PubMed ID: 34285060
[TBL] [Abstract] [Full Text] [Related]
2. Refinement of risk stratification for childhood rhabdomyosarcoma using foxo1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract] [Full Text] [Related]
3. clinical and Cytogenetic Profiles of Rhabdomyosarcoma with bone Marrow Involvement in Korean Children: A 15-Year Single-Institution Experience.
Lee DH; Park CJ; Jang S; Cho YU; Seo JJ; Im HJ; Koh KN; Cho KJ; Song JS; Seo EJ
Ann Lab Med; 2018 Mar; 38(2):132-138. PubMed ID: 29214757
[TBL] [Abstract] [Full Text] [Related]
4. Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.
Krsková L; Mrhalová M; Sumerauer D; Kodet R
Virchows Arch; 2006 Apr; 448(4):449-58. PubMed ID: 16365729
[TBL] [Abstract] [Full Text] [Related]
